GlassScriptPhysician profile
Jaydeep S Kadam
NPI 1023254612
$24,980.28
in general payments reported to CMS, 2019-2025
45 companies · $4,649 in 2025
The $4,649 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,481 · 2020: $2,048 · 2021: $3,435 · 2022: $3,407 · 2023: $4,344 · 2024: $4,615 · 2025: $4,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,608.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,484.82 | 2019-2025 | |
| Intra-Sana Laboratories | $3,101.93 | 2022-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,989.55 | 2019-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $1,447.91 | 2020-2023 | |
| Genzyme Corporation | $1,250.96 | 2022-2025 | |
| Madrigal Pharmaceuticals | $1,180.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $1,125.61 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $942.12 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $758.13 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $747.07 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $739.71 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Redhill Biopharma INC. | $664.99 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Novo Nordisk INC | $622.11 | 2023-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $509.99 | 2022-2025 | Camzyos, Zeposia |
| Janssen Pharmaceuticals, INC | $499.97 | 2019-2024 | Xarelto |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $385.66 | 2019-2023 | Sutab |
| Lilly USA, LLC | $369.77 | 2024-2025 | Omvoh, Zepbound |
| Pfizer INC. | $335.98 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $310.20 | 2023-2025 | Voquezna |
| Celgene Corporation | $259.60 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $237.54 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $229.09 | 2019-2023 | Rebyota, Cimzia |
| Olympus America INC. | $226.89 | 2023 | Evis Exera Lll Colonovideoscope |
| Vivus LLC | $224.32 | 2022-2025 | Qsymia, Pancreaze |
| Ipsen Biopharmaceuticals, INC | $202.72 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $202.09 | 2024-2025 | Zenpep |
| Enterra Medical, INC. | $190.96 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $182.29 | 2023 | Assure Wcd |
| Medtronic Vascular, INC. | $154.94 | 2020 | |
| Dova Pharmaceuticals | $154.20 | 2019 | |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.59 | 2021 | |
| Alnylam Pharmaceuticals INC. | $118.39 | 2021 | |
| Daiichi Sankyo INC. | $115.78 | 2019-2022 | |
| Allergan, INC. | $111.36 | 2019-2020 | |
| Evoke Pharma, INC. | $102.54 | 2021-2025 | |
| Gilead Sciences, INC. | $96.98 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $93.13 | 2022-2025 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $78.37 | 2023-2025 | Monoferric |
| Cumberland Pharmaceuticals, INC. | $76.39 | 2024 | Kristalose |
| Stryker Corporation | $71.43 | 2019 | |
| Endo Pharmaceuticals INC. | $65.62 | 2019-2020 | |
| Alfasigma USA, INC. | $27.54 | 2020-2021 | |
| Concordia Pharmaceuticals INC. | $21.87 | 2019 | |
| Valinor Pharma, LLC | $20.08 | 2023 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaydeep Kadam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.